[1] Rodriguez AC,Schiffman M,Herrero R,et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections [J]. J Natl Cancer Inst,2008,100(7): 513-517. [2] Watanabe M,Kono K,Kawaguchi Y,et al. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma [J]. Br J Cancer,2010,102(3):520-529. [3] 陈庆云,卞美璐,陈志华,等.宫颈癌癌前病变中人乳头瘤病毒16整合状态的检测[J].中华医学杂志,2005,85:400-404. [4] Boulet GA,Benoy IH,Depuydt CE,et al. Human Papillomavirus 16 load and E2/E6 ratio in HPV16-positive women:biomarkers for cervical intraepithelial neoplasia>or=2 in a liquid-based cytology setting? [J].Cancer Epidemiol Biomarkers Prev,2009,18 (11): 2992-2999. [5] De Freitas AC,Gurgel AP,Chagas BS,et al. Susceptibility to cervical cancer:an overview [J].Gynecol Oncol,2012,126(2):304-311. [6] Hafner N,Driesch C,Gajda M,et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts[J].Oncogene,2008,27(11):1610-1617. [7] Saunier M,Monnier-Benoit S,Mauny F,et al. Analysis of human papillomavirus type 16(HPV16) DNA laod and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma[J]. J Clin Microbiol,2008,46(11):3678-3685. [8] Visser J,Nijman HW,Hoogenboom BN,et al. Frequencies and role of regulatory T cells in patients with (pre) malignant cervical neoplasia[J]. Clin Exp Immunol,2007,150(2):199-209. [9] Sasagawa T,Takagi H,Makinoda S. Immume responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer[J]. J Infect Chemother,2012,18(6): 807-815. |